Rohto Pharmaceutical Co.,Ltd.
Notice of Share Buyback Status and Completion
Acquirements of treasury shares up to approximately 3.0 billion yen, acquisition period from 2026/8/7 to 2026/9/14, shares acquired: 1,038,600 ordinary shares, total amount about 2,999,998,289 yen. Acquisition completed via market purchases. At the time of the March 26, 2026 Board resolution, the cap was 1,500,000 shares and 30 billion yen, with progress showing 69.24% in shares and completed total amount.
Key Figures
- Total number of treasury shares acquired: 1,038,600 shares
- Total amount of acquisition: 2,999,998,289 yen
- Acquisition period: 2026 August 7 – 2026 September 14
AI要約
Acquisition Overview
Lotte Pharmaceutical conducted and completed a treasury share acquisition based on Corporate Act Article 459, Paragraph 1. The target is ordinary shares, with a total acquisition of 1,038,600 shares and total amount of about 29.9998 billion yen. Acquisition period was from August 7, 2026 to September 14, 2026, and the method was market purchases. At the Board resolution, the cap was 1,500,000 shares and 30 billion yen, with progress showing 69.24% of shares acquired and total amount completed.
Background and Impact
This treasury share acquisition is positioned as a shareholder return measure, likely aimed at mitigating dilution and stabilizing shareholder value. With the end of the acquisition period, there may be implications for near-term share float. Attention is needed regarding future capital policy directions and shareholder returns.
Rohto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
